BioArctic: Marketing Authorization Application for lecanemab

STOCKHOLM, June 8, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has submitted a marketing authorization application for lecanemab

Related Keywords

Canada , Uppsala , Uppsala Lan , Sweden , Japan , United Kingdom , Zeiten , Mecklenburg Vorpommern , Germany , Stockholm , South Korea , China , Swedish , Great Britain , Stefan Klotter , Oskar Bosson , National Institutes Of Health , Alzheimer Network Trials Unit , Vp Communications , National Institute On , Washington University School Of Medicine , Ministry Of Food , Drug Administration , Advisory Committee , Uppsala University , Alzheimer Clinical Trial Consortium , Nasdaq Stockholm , Drug Safety , Brand Name , Biologics License Application , Priority Review , Prescription Drug User Fee Act , Innovative Licensing , Access Pathway , Clinical Trial Consortium , National Institute , National Institutes , Tau Nexgen , Dominantly Inherited , Washington University School , Commercialization Agreement , Nasdaq Stockholm Large Cap , Authorization Application , Stabile Ertr , Chart Profi Stefan Klotter , Blue Chips , Bioarctic , Marketing , Authorization , Application , Lecanemab , Treatment , Early , Lzheimer , Disease , Iled , Mouth , Korea ,